Merck inks another deal to test Keytruda combinations
This article was originally published in Scrip
Merck & Co continued its streak of immuno-oncology dealmaking in a strategic clinical research collaboration with the University of Texas MD Anderson Cancer Center to test Keytruda (pembrolizumab) in combination with other treatments in three specific tumor types.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.